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The beta-adrenergic and calcium channel blocking drugs,
which individually and combined have proven efficacious
in the treatment of angina pectoris, appear to have op-
posing effects on coronary artery vasomotion. Previous
studies have shown that beta-adrenergic blockade may
potentiate and calcium channel blockade reverse coro-
nary vasoconstriction during adrenergic cold stimulation
in patients with coronary artery disease. To assess the
coronary hemodynamic effects of combined drug ther-
apy, thermodilution coronary sinus and great cardiac
vein flow and mean arterial pressure were measured
during serial cold pressor testing, both before and after
0.1 mg/kg of intravenous propranolol and again after
the addition of 10 mg of sublingual nifedipine in 21 pa-
tients (9 without [group AI] and 12 with [group A2]
>50% narrowing of the left anterior descending coro-
nary artery). In an additional 15 patients (6 patients
without [group Bl] and 9 with [group B2] left anterior
descending artery stenosis), serial cold pressor testing
was performed reversing the drug order.
Despite significant increases in mean arterial pressure
(p < 0.01) during cold pressor testing, coronary sinus
resistance responses after propranolol plus nifedipine
were not statistically significant for any group. However,
regional coronary resistance responses differed between
Angina pectoris refractory to therapy with beta-adrenergic
blocking drugs may respond to the addition of a calcium
channel blocking drug (1-3). Despite the proven clinical
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patients with and without left anterior descending artery
stenosis. In group AI, great cardiac vein resistance was
unchanged after propranolol plus nifedit>ine. In group
A2, great cardiac vein now decreased significantly after
propranolol plus nifedipine from 8 ± 17 to - 4 ± 12%
(p < 0.01 versus control), and great cardiac vein re-
sistance increased from 4 ± 21 to IS ± 19% (p < 0.01
versus control). A similar significant response was ob-
served for groups BI and 82.
Regional coronary vasoconstriction during adrener-
gic stimulation after combined drug therapy was only
observed in patients with significant left anterior de-
scending artery stenosis. These data suggest that in some
patients with severe coronary artery disease, combined
beta-adrenergic and calcium channel blockade modified
regional coronary responses to adrenergic stimulation
with an inhomogeneous distribution of blood flow to po-
tentially ischemic regions without affecting total coro-
nary blood flow. These data also imply that an improve-
ment in anginal symptoms after combined drug therapy
may be due primarily to mechanisms that reduce myo-
cardial oxygen demand rather than to improved myo-
cardial oxygen supply.
(J Am Coli CardioI1985;5:1438-50)
efficacy of combined beta-adrenergic and calcium channel
blocker therapy for angina, the mechanisms responsible for
this improvement are unclear. Calcium channel blocking
drugs may relieve myocardial ischemia by direct coronary
artery dilation (4 ,5) , increased collateral flow (6,7), reduced
myocardial oxygen demand due to diminished left ventric-
ular wall stress, decreased myocardial contractility or a com -
bination of these factors (8-12) . Controversy exists whether
calcium channel blocking agents can dilate stenotic, often
calcific, artery segments at rest or during exercise (13 ,14).
Beta -adrenergic blocking drugs, although equally effective
as calcium channel blocking drugs for anginal therapy, may
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have adverse clinical effects resulting from increased coro-
nary vasomotor tone. Propranolol potentiates alpha-adren-
ergic coronary vasoconstriction during cold pressor testing
in some patients (15), while nifedipine has been shown to
reverse adrenergically induced increases in coronary vas-
cular resistance during cold pressor testing in patients with
coronary artery disease (16). Moreover, because coronary
vasomotor tone may respond differently to adrenergic com-
pared with metabolic stimuli (17), the vasodilating prop-
erties of calcium channel blocking drugs during adrenergic
stimulation may be reduced by concomitant beta-adrenergic
blockade.
Accordingly, the purpose of this study was to assess the
effects of combined therapy with a beta-adrenergic and a
calcium channel blocking drug on total and regional coro-
nary vascular responses during adrenergic stimulation. We
tested the hypothesis that the administration of a calcium
channel blocking drug would reverse or attenuate adrener-
gically mediated coronary vasoconstriction induced by cold
pressor testing after beta-adrenergic blockade.
Methods
Study patients. We studied 36 patients scheduled for
routine cardiac catheterization for chest pain. Patients were
excluded if any of the following were present: unstable
angina, coexistent valvular heart disease, severe left ven-
tricular dysfunction, 50% or greater left main coronary ar-
tery stenosis identified during diagnostic cardiac catheter-
ization, myocardial infarction within 4 weeks of the study
or contraindications to the administration of beta-adrenergic
or calcium channel blocking agents. Patients were separated
into two groups depending on the order of drug adminis-
tration. Group A was given intravenous propranolol fol-
lowed by sublingual nifedipine. Group B was given nifed-
ipine followed by propranolol. Subgroups were then defined
by coronary anatomy. Groups Al and Bl included patients
with insignificant stenosis of the left anterior descending
coronary artery stenosis, while groups A2 and B2 had 50%
or greater narrowing of this artery.
Investigational protocol. The investigational protocol
was approved by the Human Subjects Committee of the
Institutional Review Board at the University of Texas Health
Science Center at San Antonio and the Audie L. Murphy
Veterans Administration Hospital. After written informed
consent was obtained, all beta-adrenergic blocking drugs,
calcium channel blocking agents and long-acting nitrates
were withheld for at least 12 to 18 hours before the study.
Short-acting nitrate preparations were withheld at least 6
hours before cardiac catheterization. No routine precathe-
terization medications were administered.
After completion of diagnostic cardiac catheterization
including coronary angiography and left ventriculography,
a coronary sinus triple thermistor thermodilution bipolar
pacing catheter (Wilton Webster Laboratories) was posi-
tioned by way of an antecubital vein under fluoroscopic
guidance. The distal thermistor was advanced to the great
cardiac vein, and its position verified with injection of 3 to
5 ml of radiographic contrast material. The catheter position
was kept constant throughout the study and verified by pe-
riodic fluoroscopy. A 6F NIH catheter was also inserted
into the coronary sinus to facilitate measurement of blood
oxygen content. Test flow signals before each study con-
firmed that the addition of this catheter did not interfere
with the thermodilution signals or coronary sinus pacing.
Left ventricular end-diastolic pressure was measured with
a fluid-filled catheter in 13 patients and with a high fidelity
micromanometer-tipped catheter (Millar instruments) in 23
patients. Supplemental heparin (3,000 to 5,000 units, in-
travenously) was administeredafter catheter placement. Right
atrial pressure was recorded in all patients with a 7F balloon-
tipped catheter introduced through a femoral vein. The phasic
and mean arterial pressures were measured through a fluid-
filled femoral artery catheter. All pressures, coronary flow
signals and electrocardiogram were recorded on a multi-
channeloptical strip chart recorder (Electronicsfor Medicine).
Measurements. Data collection was begun at least 15
minutes after radiographic contrast injection to minimize
myocardial metabolic alterations induced by contrast ma-
terial (18). Phasic and mean arterial pressures, right atrial
pressure, left ventricular systolic and end-diastolic pres-
sures, electronically derived first derivative of left ventric-
ular pressure (dP/dt) (from high fidelity ventricular catheters
only), coronary sinus and great vein blood flow signals and
simultaneous arterial and paired coronary sinus blood sam-
ples were obtained at rest and during serial cold pressor
testing. Cold pressor testing was performed as described in
previous studies (15-17,19). In brief, cold pressor testing
measurements were obtained continuously after 2 minutes
of coronary sinus pacing at a mean (± SD) constant sub-
anginal heart rate of 95 ± 5 beats/min and during appli-
cation of ice water to the patient's hand and forearm for 90
seconds. Figure 1diagrammatically illustrates the study pro-
tocol. For groups Al and A2, measurements were obtained
during three cold pressor tests: control, 3 minutes after 0.1
mg/kg of propranolol intravenously and 5 minutes after 10
mg of sublingual nifedipine. Each cold pressor test was
followed by an equilibration period of 5 minutes to allow
hemodynamic variables to return to baseline.
Propranolol and nifedipine administration. Propranolol
was administered intravenously in three divided doses, with
each dose (0.033 rug/kg) given over 1 minute and with a 2
minute observation period between doses. The total dose of
propranolol (0.1 mg/kg) has been used by other investigators
(20) to achieve beta-adrenergic blockade. Heart rate, elec-
trocardiogram and left ventricular end-diastolic pressure were
monitored during the administration of propranolol. No pa-
tient required termination of propranolol administration ac-
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CPT = Rest~ Pacing 95 beat/min ~ CPT~ Equilibration
Ice Ice
On Off
Figure 1. Study protocol. Ao = phasic
aortic pressure; Art = arterial oxygen
content; CPT = cold pressor testing;
CSF = coronary sinus blood flow; CS02
= coronary sinus oxygen content; OCVF
= great cardiac vein flow; IV = intra-
venously; LVED = left ventricular end-
diastolic pressure; MAP = mean arterial
pressure; RA = right atrial pressure;
SL = sublingually.
Ao, MAP, RA, LVED, }
CSF, GCVF
Art, CS02
time (min)
Groups
i I
A1 and A2
Groups
i I
81 and 82
=X
Control CPT CPT CPT
\'propranololJ ~NifediPine j
0.1 mg/kg IV 10 mg SL
Control CPT CPT CPT
~NifediPine.J ~propranoIOI.Y
10 mg SL 0.1 mg/kg IV
cording to the predetermined criteria of a PR interval pro-
longation of greater than 0.24 second or higher degree
atrioventricular (AV) block, greater than 8 mm Hg increase
in left ventricular end-diastolic pressure from control, de-
crease in basal heart rate to less than 45 beats/min or less
than 15 mm Hg reduction in systolic arterial pressure from
control. Hemodynamic and coronary flow measurements at
rest and during cold pressor testing were obtained 3 minutes
after the last dose of propranolol. The dose of 10 mg of
sublingual nifedipine has been shown (21) to increase coro-
nary blood flow at rest without causing significant hypo-
tension or reduction in left ventricular contractility. Five
minutes after the administration of nifedipine, repeat hemo-
dynamic and coronary flow measurements were obtained at
rest and during cold pressor testing.
In groups Bland B2, all coronary flow and hemodynamic
measurements for the three cold pressor tests were obtained
in an identical fashion, but with the order of drug admin-
istration reversed. For these patients, 10 mg of sublingual
nifedipine was given 5 minutes after the initial control cold
pressor test. Five minutes later, rest and cold pressor test
measurements were obtained. After a second 5 minute equil-
ibration period, 0.1 mg/kg of propranolol was administered
intravenously, and 3 minutes later, rest and cold pressor test
measurements were obtained.
In 32 patients, simultaneous arterial and coronary sinus
blood samples were taken to determine oxygen content and
myocardial oxygen consumption during each study period.
Data analysis. All blood samples were analyzed for ox-
ygen content using an I. L. Co-oximeter 282 (Instrumen-
tation Laboratory Inc.) and the data was compared with
results of fuel cell oximetry (Lex-Oy-Con) for accuracy.
Coronary sinus and great cardiac vein blood flows were
calculated by the method of Ganz et al. (22). Great cardiac
vein flow signals reflect the venous efflux from the left
ventricular region supplied predominantly by the left an-
terior descending coronary artery and were thus used as a
measure of anterior myocardial blood flow. Total coronary
sinus efflux was used to estimate both anterior and inferior
left ventricular blood flow. Each thermodilution coronary
flow value was the average of five calculations made over
a 10 second interval. Variation of coronary flow values over
the measurement period was less than 10%. Coronary vas-
cular resistance was calculated as the quotient of mean ar-
terial pressure and either coronary sinus or great cardiac
vein flow (19). Systolic, diastolic, mean arterial, right atrial
and left ventricular end-diastolic pressures were measured
simultaneously with the coronary sinus flow signals. Peak
first derivative of left ventricular pressure (dP/dt) was elec-
tronically derived from the first derivative of left ventricular
pressure only when using the high fidelity micromanometer-
tipped catheters. Myocardial oxygen consumption was cal-
culated as the product of coronary sinus blood flow and
arterial-coronary sinus oxygen content difference.
Statistical analysis. Each patient served as his own con-
trol. The effects of propranolol or nifedipine individually
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and the combination of the two drugs on the rest and cold
pressor testing responses were examined by one way anal-
ysis of variance. Whenever such analysis indicated that a
significant difference existed, subsequent comparisons be-
tween groups were performed using paired t tests. The Bon-
ferroni modification (23) for three comparisons (control, one
drug and combination drugs) was used, and statistically
significant comparisons were noted at p < 0.02. For paired
data not involved in multiple comparisons, statistical sig-
nificance was noted at p < 0.05. Data are reported as mean
values 2: standard deviation.
Results
Clinical data. Rest right heart hemodynamic and an-
giographic data of the study are summarized in Table 1. All
36 patients were men. Five of the nine patients in group Al
(propranolol plus nifedipine) and all six patients in group
B1 (reverse drug order) had an angiographically normal or
insignificantly diseased left anterior descending coronary
artery. All 12 patients in group A2 (propranolol plus nifed-
ipine) and seven of nine patients in group B2 (reverse drug
order) had greater than 70% left anterior descending artery
stenosis; the two remaining group B2 patients had greater
than 50% left anterior descending artery stenosis. The extent
of coronary artery disease involving the circumflex and right
coronary arteries was greater in group A1 than in group B1.
Atypical angina was the presenting symptom in four of six
patients in group Bland two of nine patients in group AI.
Significant (> 50%) coronary artery disease involving the
circumflex or right coronary artery, or both, was present in
24 of 36 patients. There was no correlation with extent of
disease in the right or circumflex coronary artery and the
cold pressor testing responses.
There were no differences among groups with respect to
age, right heart hemodynamics or left ventricular ejection
fraction. Regions of abnormal left ventricular wall motion
were present in at least half the patients in groups AI, A2
and B2. Only one patient in group B1 had a minimal left
ventricular wall motion abnormality. Coronary collateral
flow to the left anterior descending artery was present in
one patient in group A2, and to the right coronary artery in
two patients in group B2. The response to cold pressor
testing before and after combination drug therapy in these
patients did not differ from the group data. One patient
(group A2) had angina during initial but not subsequent cold
pressor testing. One had angina after the administration of
nifedipine (group B2), but not during the administration of
nifedipine and propranolol.
Rest hemodynamic and metabolic responses after beta-
adrenergic and calcium channel blocking drugs. Rest
hemodynamic and metabolic data for all patient groups be-
fore and after propranolol, nifedipine and their combination
are summarized in Table 2. There were no significant effects
of combined propranolol and nifedipine on systolic, dia-
stolic or mean arterial pressures at rest except in group B2.
In this group, both systolic and diastolic blood pressures
were reduced from the control value (from 145/80 to 133/77
mm Hg, p < 0.03 versus control) after combined nifedipine
and propranolol. Left ventricular end-diastolic pressure in-
creased from the control value (from 11 2: 7 to 15 2: 7
mm Hg, p < 0.03 versus control) after propranolol admin-
istration only in group AI. Left ventricular end-diastolic
pressure was unchanged after drug administration in the
remaining groups.
Propranolol administration reduced heart rate from 69 2:
15 to 63 2: 13 beats/min (p < 0.02 versus control) in group
AI, and from 67 2: 7 to 62 2: 5 beats/min (p < 0.03 versus
control) in group A2. These changes returned toward control
values after nifedipine was added. In groups Bland B2,
the addition of propranolol to nifedipine resulted in an in-
significant decrease in heart rate toward control values (from
67 2: 11 to 64 2: 9 beats/min in group B1, and from
72 2: 12 to 69 2: 10 beats/min for group B2).
Rest total coronary sinus and great cardiac vein flow
and resistance were similar for all groups under rest con-
ditions. Coronary sinus oxygen content was significantly
higher after combined drug therapy in groups AI and B2,
but there was no significant difference in the calculated
myocardial oxygen consumption among all groups at rest.
An additional index of myocardial work, dP/dt, showed no
significant change after combined drug therapy. For groups
Al and A2, propranolol reduced peak dP/dt by 9% from
1,578 2: 300 to 1,442 ± 300 mm Hg/s (p = NS), while
dP/dt was not further affected after the addition of nifedipine
(1,462 2: 400 mm Hg/s, p = NS). In groups Bl and B2,
dP/dt was 1,487 ± 250 mm Hg/s before and 1,459 ± 350
mm Hg/s after the administration of nifedipine (p = NS)
with the addition of propranolol reducing dP/dt by 8% from
1,459 ± 350 to 1,349 ± 270 mm Hg/s (p = NS).
Hemodynamic and metabolic responses to cold pres-
sor testing after combined beta-adrenergic and calcium
channel blocking drugs. Hemodynamic and metabolic data
during cold pressor testing for all groups are summarized
in Table 3. During cold pressor testing, systolic and mean
arterial pressures increased significantly (p < 0.01) in all
groups for each study condition. Changes in diastolic arterial
and left ventricular end-diastolic pressures were variable.
There were no consistently significant changes in the coro-
nary sinus oxygen content, arterial coronary sinus oxygen
content difference or calculated myocardial oxygen con-
sumption during cold pressor testing.
Total coronary sinus flow responses during cold pressor
testing are summarized in Table 4. Great vein flow responses
are summarized in Table 5 and Figure 2. Total coronary
sinus flow and resistance responses during cold pressor test-
ing were not statistically different among the three study
conditions for any patient group.
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Table 1. Baseline Clinical and Hemodynamic Data in Patients Without (Groups Al and B'l) and With (Groups A2 and B2) 50% or
Greater Stenosis of the Left Anterior Descending Coronary Artery
Age Drug B/Blk C/BIk
Pressure (mm Hg)
EF LAD LCx RCA
Case (yr) Therapy (mg/day) (mg/day) RA PA (SID) (%) LVWM Loc (%) (%) (%)
Group AI (propranolol plus nifedipine)
I 62 NF,IS 0 120 4 20/6 72 WNL 40 50 40
2 60 PR,NF,DI 160 80 I 2115 79 WNL 50 0 99
3 38 PR,NF 960 120 0 16/8 58 WNL 30 0 70
4 71 IS,NF 0 30 0 20/8 58 Akn Inf 40 0 100
5 54 NF,DI 0 40 I 16/4 75 WNL 0 0 0
6 62 0 0 3 22/8 57 Akn Inf 0 40 100
7 62 PR 240 0 0 22/6 55 Dys Inf 0 80 100
8 62 NA,NF,IS 120 80 3 18/8 61 WNL 0 0 0
9 54 PR,NF,DI 240 30 4 29113 62 Akn Inf 0 0 65
Mean 58 ± 9 2 ± 2 20 ± 4/7 ± 3 64 ± 9
± SD
Group A2 (propranolol plus nifedipine)
10 52 NA,IS 80 0 4 28/10 64 Akn Inf 99 90 100
11 71 PR,NF,IS 240 40 2 18/9 71 WNL 100 90 90
12 59 PR,IS 160 0 3 18/10 73 Hyp Inf 90 100 100
13 60 PR,NF 320 80 3 24/10 70 WNL 95 50 90
14 60 IS 0 0 2 26/9 53 Hyp Ant 90 99 90
15 57 NA,IS,DI 80 0 0 18/3 77 WNL 95 70 0
16 39 PR,NF 640 80 2 23/7 72 WNL 95 100 100
17 57 PR 240 0 7 22/11 57 Akn Inf 75 50 100
18 57 MT,NF,IS 100 90 5 18/11 56 Akn Api 90 30 80
19 48 PR,DZ,DI 480 360 2 18/6 66 WNL 70 70 90
20 52 PR,NF,IS 800 80 3 32/14 58 WNL 95 30 0
21 64 PR,IS 480 0 I 26/10 48 Hyp Inf 100 70 0
Mean 56 ± 8 3 ± 2 23±5/9±3 64 ± 9
± SD
Group BI (nifedipine plus propranolol)
22 65 PR,IS 240 0 2 22/6 74 WNL 0 0 0
23 60 IS 0 0 6 26/14 63 WNL 0 0 40
24 31 IS 0 0 5 18/12 68 WNL 0 0 0
25 43 DZ,IS 0 240 5 23/7 63 WNL 0 0 0
26 64 PR 240 0 4 38/14 59 Hyp AAp 0 0 0
27 54 PR,IS 240 0 5 24/10 70 WNL 0 0 0
Mean 52 ± 13 5 ± 25 ± 7/11 ± 3 66 ± 5
± SD
Group B2 (nifedipine plus propranolol)
28 63 DI 0 0 2 20/8 48 Dys AAp 80 0 0
29 61 PR,IS 240 0 6 31/16 39 Hyp Inf 75 100 100
30 55 PR,IS 240 0 0 18/6 58 Hyp Api 80 90 100
31 60 MT,NF,IS 75 30 4 24/9 75 WNL 70 100 90
32 65 PR,NF,IS 960 80 4 22/10 47 Akn Inf 70 90 90
33 52 0 0 3 22/10 49 Akn Inf 60 95 100
34 55 PR,IS 480 0 5 30/14 82 WNL 95 0 50
35 55 PR,NF,IS 80 60 6 20/8 54 Akn Inf 70 100 100
36 65 PR,IS 100 0 3 22/8 67 WNL 50 100 100
Mean 59 ± 5 4 ± 2 23 ± 4/10 ± 3 58 ± 4
± SD
AAp = anterior apical; Ant = anterior; Api = apical; B/Blk = beta-adrenergic blocking drug; C/BIk = calcium channel blocking drug; D =
diastolic; DI = diuretic drug; DZ = diltiazem; EF = angiographic left ventricular ejection fraction; Inf = inferior; IS = isosorbide dinitrate;
LAD (%) = percent diameter narrowing of the left anterior descending coronary artery; LCx (%) = percent diameter narrowing of the left circumflex
coronary artery; Loc = location of the left ventricular wall motion abnormality; LVWM = left ventricular wall motion abnormality, single plane
angiographically observed akinesia (Akn), dyskinesia (Dys) or hypokinesia (Hyp) in one or more segments; MT = metoprolol; NA = nadolol; NF =
nifedipine; PA = pulmonary artery; PR = propranolol; RA = right atrial; RCA (%) = percent diameter narrowing of the right coronary artery; S =
systolic; WNL = within normal limits.
Table 2. Rest Hemodyn am ic and Metabolic Dat a Before and After Combined Bet a- and Calcium C ha nnel Blockad e
Blood Pressure (mm Hg)
HR CSF CSR GVF GVR A-CS0 2** CS02 ** MY0 2**
Systolic Diastolic MA LVED (beats/min) (mllmin) (mm Hg-rnin-ml" ') (rnl/rnin) (mm Hg-min-ml" ') (mild)) (mild)) (ml/min)
Group A l
C 149 ± 18 76 ± 17 107 ± 17 II ± 7 69 ± 15 95 ± 53 1.45 ± 0.86 63 ± 27 2. 25 ± 1.64 12.1 ± 1.3 s.o ± 0 .7 13.1 ± 7 .5
P 158 ± 22 77 ± 17 108 ± 19 15 ± 7* 63 ± 13* 76 ± 51 1.78 ± 0.89 61 ± 36 2.55 ± 1.87 11.8 ± 1.2 5.3 ± 0 .7 9 .5 ± 7.9
P+N 158 ± 20 78 ± 15 109 ± 16 15 ± 6 65 ± 13 69 ± 25 1.99 ± 0.75 64 ± 34 2.46 ± 1.85 11.6 ± 1.5 5.7 ± 0 .7t 7.9 ± 3.0
Group A2
C 150 ± 2 1 74 ± 8 103 ± 12 13 ± 5 67 ± 7 82 ± 19 1.28 ± 0.30 62 ± 28 1.88 ± 0.66 11.5 ± 1.4 6 .5 ± 1.9 8.3 ± 8.5
P 153 ± 18 76 ± 7 107 ± 9 15 ± 5 62 ± 5* 86 ± 2 1 1.28 ± 0.35 63 ± 22 1.90 ± 0 .68 11.4 ± 2. 1 6 .6 ± 1.8 9 .7 ± 2 .3
P+N 145 ± 15 74 ± 5 103 ± 6 13 ± 6 66 ± 9 86 ± 20 1.25 ± 0.33 69 ± 36 1.83 ± 0 .85 10.9 ± 1.8 6 .9 ± 1.7 8.4 ± 8.8
Group B1
C 141 ± 29 79 ± 5 104 ± 12 14 ± 3 64 ± 12 113 ± 80 1.36 ± 0.89 53 ± 27 2.42 ± 1.07 13.4 ± 2.8 6 .7 ± 2.6 17.2 ±11.3
N 137 ± 23 79 ± 6 104 ± 12 14 ± 3 67 ± II 128 ± 94 1.26 ± 0 .84 5 1 ± 20 2.28 ± 0 .71 12.1 ± 2.4 7 .6 ± 2.5 17.3 ± 11.4
N+P 131 ± 24 74 ± 4 99 ± 10 14 ± 7 64 ± 9 104 ± 67 1.21 ± 0. 57 48 ± 13 2. 16 ± 0 .55 11.4 ± 2.2 8.3 ± 2.8 13.4 ± 8.6
Gro up B2
C 145 ± 26 80 ± 13 106 ± 17 15 ± 9 68 ± 12 81 ± 30 1.46 ± 0 .45 59 ± 16 1.90 ± 0.50 12.2 ± 1.4 6.0 ± 1.0 9.4 ± 3.0
N 144 ± 24 '83 ± 16 106 ± 16 15 ± 6 72 ± 12 104 ± '45 1.15 ± 0.41 73 ± 25 1.55 ± 0.41 12.3 ± 1.5 .6. 1 ± 1.0 11.8 ± 4 .0
N+P 133 ± 22* 77 ± 13:1: 102 ± 17 15 ± 5 69 ± 10 97 ± 39 1.21 ± 0 .45 75 ± 27 1.48 ± 0.43 10.4 ± 1.2t § 7.4 ± 1.6t § 9.9 ± 3.3
*p < 0 .03 versus control; t p < 0 .01 versus control; :l:p < 0.05 versus nifedipine ; §p < 0 .0 1 versus nifedip ine . All data are reported as mean value s ± SD . A-
CS02 = arterial-coronary sinus oxygen content differe nce; C = control; CSF = coronary sinus blood flow ; CSO, = coro nary sinus oxygen content; CSR = coronary
sinus resistance; GVF = great cardiac vein flow; GVR = great cardiac vein resistance; HR = heart rate; LVED = left ventricu lar end-diastolic; MA = mean arterial ;
MY02 = arterial-coronary sinus oxygen content difference x coronary sinus blood flow; N = post-nifedipine; N + P = post-nifedipine plus propran olol ; **patient
number (n) for group A I = 7, A2 = 9, B1 = 5 and B2 = 9; P = post-propranolol ; P + N = post-propranolol plus nifedip ine.
Table 3. Hemodynamic and Metaboli c Responses to Cold Pressor Testing Before and After Combined Beta-Adrenergic and Calcium Channel Blockade
Blood Pressure (mm Hg)
A-CS02 CS0 2 MV0 2
Systolic Diastolic LVED MA (mlldl ) (mlldl) (mllmin)
Pacing CPT Pacing CPT Pacing CPT Pacing CPT Pacing CPT Pacing CPT Pacing CPT
Group Al
C 146 ± 20 162 ± 21" 84 ± II 90 ± 16t 8 ± 5 12 ± 6" 108 ± 14 121 ± 16" 12.1 :!: 1.4 11.3 :!: 1.2" 5.7 :!: 0 .8 5.9 ± 0.8 14.5 :!: 8 .9 14.5:!: 10 .0
P 151 ± 22 164 ± 22" 86 :!: 13 93 :!: 13" 9 ± 5 12 ± 7t 113 ± 16 123 :!: 15" 11.8 :!: 1.5 11.8 :!: 1.2 5.4 :!: 0. 8 5.3 :!: 0 .8 12.0 :!: 8.1 12.3 :!: 8.4
P+N 148 :!: 19 156 ± 20" 85 :!: 13 90 ± 14t 8 :!: 6 12 ± 4 112 ± 14 120 ± 15" 11.7 ± 1.4 11.2 ± 1.5 5.9 ± 0 .8 6.1 ± 1.0 9.0 ± 3.6 9.8 ± 4 .9
Group A2
C 155 ± 22 163 ± 20" 89 ± 6 84 ± 6 10 ± 7 13 ± st 113 ± 10 124 ± 12" I I.l ± 1.9 11.2 ± 2.2 7.0 ± 2. 1 6.7 ± 2.2 13.5 ± 8.4 12.6 ± 5.6
P 149 :!: 25 163 ± 20" 84 :!: 6 94 :!: 6" 10 ± 7 13 ± 8" 113 ± 10 126 ± 13" 11.2 :!: 1.8 11.0 ± 2.0 6.8 ± 2. 1 6.8 :!: 2.2 14.5 ± 6.8 15.2 :!: 7.4
P+N 141 ± 14 156 ± 19" 82 ± 6 89 ± 5" 8 ± 4 12 ± 5" 108 ± 7 118 ± 8" 10.6 ± 1.5 10.3 ± 1.7 7.6 ± 2.1 7.7 ± 2.3 14.3 ± 4.3 15.4 ± 5.2
Group BI
C 145 :!: 30 155 ± 31" 94 ± 10 100 ± 8 10 ± 2 14 ± 4t 118 ± 12 125 ± 18" 13.2 ± 2.6 12.5 ± 2.5 7.1 ± 2.5 7.2 ± 2.5 20.5 :!: 12.7 23.2 ± 14.8
N 134 ± 22 143 ± 30" 85 ± 3 91 ± 6 9 ± 4 10 ± 5 107 ± 10 116 ± 13" 11.9 :!: 2.9 11.6 ± 1.9 7.9 ± 2.7 9.0 ± 3. 1 24.8 ± 18.2 23.3 ± 12.8
N+P 133 :!: 20 142 ± 26" 86 ± 3 93 :!: 7 11 ± 5 14 ± 6 107 ± 10 115 ± 15" 11.5 ± 1.7 11.3 ± 1.9 8.0 ± 2.5 8.9 ± 2.5 20.2 :!: 15.0 17.3 :!: 8 .7
Group B2
C 144 ± 24 164 ± 22" 92 ± 15 101 ± 14" 11 ± 10 17 ± II " 115 :!: 19 129 ± 16" 12.2 ± 1.3 12.2 ± 1.2 6.3 ± 1.9 6.2 ± 0.9 11.5 ±2.9 12.5 ± 4. 1
N 137 :!: 23 155 ± 23" 87 ± 12 94 :!: 13t 12 ± 8 15 ± 10 109 ± 16 121 ± 16" 11.7 ± 1.0 11.1 ± 0.7 6.5 ± 1.2 6.7 ± 1.3 11.6 ± 3.7 13.2 ± 5.5
N+P 136 ± 23 146 ± 21" 89 :!: 14 92 ± 15 10 ± 9 18 ± 11" 108 ± 13 119 ± 12" 10.6 ± I.l 10.7 ± 1.2 7.3 ± 1.6 7.3 ± 1.7 I I.l ± 3.3 12.0 ± 5.0
*p < 0.01 pacing versus cold pressor testing; t p < 0 .05 pacing versus cold pressor testing. All data are reported as mean values ± SO. CPT = cold pressor
testing; other abbreviations as in Table 2.
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Table 4. Total Coronary Sinus Flow Responses to Cold Pressor Testing Before and After Combined Beta-Adrenergic and Calcium
Channel Blockade
~MAP ~CSF ~CSF ~CSR ~CSR
(mmHg) (mllmin) (%) (mm Hg· min' m1-I ) (%)
Group C P P+N C P P+N C P P+N C P P+N C P P+N
Al 12 10 8 12 6 0 9 5 5 0.06 0.08 0.06 3 5 4
± 4 ± 5 ± 5 ± 16 ±II ± 14 ± 15 ± II ± 16 ± 0.14 ± 0.16 ± 0.28 ± 11 ±1O ±1O
A2 II 13 10 -I 2 9 I 2 6 0.08 0.12 0.05 9 13 5
± 6 ± 9 ± 5 ± 16 ± 20 ± 25 ± 12 ± 15 ± 18 ± 0.12 ± 0.20 ± 0.14 ± 12 ± 19 ± 17
C N N+P C N N+P C N N+P C N N+P C N N+P
BI 8 10 8 23 -1 -15 II 6 1 0.05 0.03 0.03 0 6 II
± 6 ± 8 ± 8 ± 53 ±44 ± 57 ± 29 ± 23 ± 24 ± 0.27 ± 0.13 ± 0.12 ± 25 ± 16 ± 24
B2 15 12 II 10 16 6 10 15 3 0.08 -0.03 0.16 7 -6 4
± 7 ±4 ± 5 ± 30 ± 24 ± 20 ± 27 ± 16 ± 19 ± 0.28 ± 0.13 ± 0.27 ± 23 ± 14 ± 22
All data are reported as mean values ± SD. Abbreviations as in Tables I and 2.
Regional great vein flow responses during cold pressor
testing demonstrated important differences among the pa-
tient groups. In group AI, great vein flow during the initial
cold pressor testing increased significantly (12 ± 17%,
P < 0.02) and was attenuated after the administration of
propranolol and combined propranolol and nifedipine. In
contrast, great vein flow during cold pressor testing in group
A2 did not significantly change after propranolol adminis-
tration (8 ± 17 to 4 ± 16%, P = NS), but significantly
decreased to -4 ± 12% (p < 0.02 versus control) after
nifedipine was added.
Changes in great cardiac resistance were parallel with
those of great vein flow. In group AI, propranolol admin-
istration did not significantly increase great vein resistance
during cold pressor testing (from 1 ± 18 to 7 ± 19%,
P = NS). After nifedipine was added, great cardiac vein
resistance returned toward the control cold pressor testing
response (3 ± 17%, P = NS). However, in group A2, the
increase in great vein resistance during cold pressor testing
(4 ± 21 to9 ± 16% after the administration of propranolol,
p = NS) was potentiated to 15 ± 19%, (p < 0.01 versus
control) after the addition of nifedipine. Figure 3 shows
individual group A2 patient responses to cold pressor testing
before and after combined therapy with propranolol and
nifedipine.
To determine whether our observations concerning great
vein resistance responses during cold pressor testing after
combined propranolol and nifedipine administration were a
function of the study protocol, we reversed the order of
beta-adrenergic and calcium channel blocking drug admin-
istration in 15 patients (groups B1 and B2, Fig. 2B). As in
groups Al and A2, the most significant changes in great
vein flow and resistance occurred in group B2. Cold pressor
testing after combined nifedipine and propranolol admin-
istration in group B1 induced an increase in great vein flow
(from - 9 ± 8 to 4 ± 12%, P < 0.03 versus control). In
group B2, the administration of nifedipine insignificantly
increased great vein flow during cold pressor testing (from
Table 5. Great Cardiac Vein Flow Responses During Cold Pressor Testing Before and After Combined Beta-Adrenergic and Calcium
Channel Blockade
~MAP ~GVF ~GVF ~GVR ~GVR
(mmHg) (mllmin) (%) (mm Hg· min' ml- I ) (%)
Group C P P+N C P P+N C P P+N C P P+N C P P+N
Al 11 9 7 11 2 4 12 5 6 0.05 0.13 0.03 I 7 3
± 4 ± 4 ± 5 ± 12 ± 17 ± 13 ± 17 ± 21 ± 22 ± 0.36 ± 0.39 ± 0.34 ± 18 ± 19 ±17
A2 10 12 9 7 5 -zt 8 4 -4t 0.08 0.17 0.24 4 9 15*
± 5 ± 7 ± 5 ± 12 ± 19 ± 12 ± 17 ± 16 ± 12 ± 0.35 ± 0.28 ± 0.25 ± 21 ± 16 ± 19
C N N+P C N N+P C N N+P C N N+P C N N+P
B1 7 9 8 -7 -2 2 -9 -I 4 0.27 0.18 0.08 17 II 4
± 4 ± 8 ± 8 ± 9 ± 6 ± 7 ±13 ± 8 ± 12 ± 0.23 ± 0.15 ± 0.28 ± 12 ± 8 ± 14
82 14 12 11 I 14 It 8 15 I§ 0.11 -0.03 0.15t 9 -2 lit
±9 ± 5 ± 5 ± 16 ± 14 ± 15 ± 25 ± 14 ± 15 ± 0.47 ± 0.14 ± 0.20 ± 21 ± II ± 15
*p < 0.01 versus control; tp < 0.02 versus control; tp < 0.02 versus nifedipine; §p < 0.01 versus nifedipine. All data are reported as mean values
± SD. Abbreviations as in Tables I and 2.
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Figure 3. Individual group A2 changes in great vein resistance
during cold pressor testing (CPT). %6 = percent change; other
abbreviations as in Figure 2.
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Figure 2. Great Vein flow (dVF) responses during cold pressor
testing (CPT) for groups Al and A2 (A) and BI and B2 (B).
CON = control; GVR = great vein resistance; ISE = I standard
error; MAP = inean arterial pressure; NIF = nifedipine; P
pacing; PROP = propranolol; U = units (mm Hg-min" ').
ure 4 summarizes the group changes during cold pressor
testing in great cardiac vein resistance before and after com-
bined beta-adrenergic and calcium channel blockade.
Discussion
This study demonstrates that after the administration of
combined beta-adrenergic and calcium channel blocking
drugs, increased adrenergic stimulation may cause regional
coronary vasoconstriction in a subset of patients with left
anterior descending coronary artery stenosis. In patients with
greater than 50% stenosis of this artery (groups A2 and B2),
cold pressor testing after combined beta-adrenergic and cal-
cium channel blocking drugs, regardless of the order of
administration, was associated with a decrease in great car-
diac vein flow and an increase in great vein resistance. These
results may be best interpreted by considering the dynamic
nature of coronary vascular resistance and the individual
AI A2 81 82
10
20
%AGVR
DuringCPT
O+--'~--
*p<.02
**p<.OI
TISE
DeON IIIINIF
1m!! PROP • PROP +NIF
-10
Figure 4. Changes in great vein resistance (GVR) during cold
pressor testing (CPT). Groups as in Table I. 6% = percent change
during control pressor testing; other abbreviations as in Figure 2.
8 ± 25 to 15 ± 14%, P = NS), but the subsequent addition
of propranolol significantly decreased great vein flow (to
1 ± 15%, P == NS versuscontrol, P < 0.01 versusnifedipine).
Parallel significant changes in great vein resistance were
also observed. In group BI, the great vein resistance was
insignificantly reduced from 17 ± 12 to 4 ± 16% (p =
N~) after the combined administration of nifedipine and
propranolol. However, in group B2, great vein resistance
during cold pressor testing increased significantly from
- 2 ± 11 to 11 ± 15% after combined beta- and calcium
channel blocking therapy (p < 0.02 versus nifedipine). Fig-
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effects of beta-adrenergic and calcium channel blocking drugs
on coronary artery vasoreactivity.
Coronary hemodynamic effects of propranolol, nifed-
ipine and cold pressor testing. As noted in earlier reports
(15-17), propranolol administration tended to potentiate al-
pha-adrenergic-mediated vasoconstrictor tone during cold
pressor testing, while nifedipine attenuated the increase in
coronary resistance during cold pressor testing. The com-
bination of both drugs reversed or attenuated the total coro-
nary resistance responses during cold pressor testing as com-
pared with those induced by either drug alone . Thus, the
combined drug effect nullified directionally opposite re-
sponses that would have been predicted on the basis of
previous studies of the two drugs individually.
Although regional coronary hemodynamics during cold
pressor testing have been studied (24-26), regional coronary
vasomotor responses to propranolol, nifedipine and the com-
bination of the two drugs have not been evaluated. Cold
pressor testing after each drug individually tended to alter
great vein resistance in parallel with changes in total coro-
nary sinus resistance. We did not anticipate the divergent
regional vasoconstrictor responses compared with total
coronary sinus responses observed in patients with left an-
terior descending coronary artery stenosis after treatment
with combined drug therapy. In groups A2 and B2, but not
groups A1 or B 1, cold pressor testing after combined pro-
pranolol and nifedipine administration increased great vein
resistance, while total coronary sinus resistance was
unaffected.
Potential mechanisms of regional coronary vasocon-
striction. Several mechanisms may explain the regional
cold pressor responses after combined drug therapy. One
possible mechanism is the inhomogeneity of post-stenotic
coronary perfusion observed with the increasing severity of
flow-limiting stenoses. Weintraub et al. (27) and others
(28,29) have shown that nifedipine may not increase myo-
cardial blood flow to regions supplied by a severely stenotic
vessel. In patients with coronary artery disease, the admin-
istration of sublingual or intravenous nifedipine in some
studies (28,30-32) increased coronary blood flow in normal
as well as diseased vessels, while other studies (13,14 ,33-35)
suggested that flow in diseased arterial segments was un-
affected. Indeed, exercise studies (2,14,36-38) that dem-
onstrated a beneficial antianginal effect at a lower rate-
pressure product and various work loads after combined
beta-adrenergic and calcium channel blocking drug therapy
provide indirect evidence that the clinical improvement may
be due primarily to reduced myocardial oxygen demand
rather than to an increased myocardial blood supply . Thus,
although nifedipine improves global coronary flow, it may
not improve blood flow through severely diseased coronary
arteries, and contributes to regional inhomogeneity of coro-
nary flow as noted in our patient groups A2 and B2.
Another potential mechanism may be a direct or indirect
drug-induced reflex sympathetic vasoconstriction (13). Ver-
apamil, nifedipine and nifedipine combined with metoprolol
have been associated with the increased release of myo-
cardial norepinephrine (39,40) . In our patients, increased
sympathetic activity due to cold pressor testing (41) and
possibly nifedipine may have contributed to regional coro-
nary vasoconstriction.
The dynamic response ofprecapillary or collateral coro-
nary arterioles to combined drug therapy may also con-
tribute to regional decreases in coronary blood flow. Gould
(42) and others (43-45) have noted paradoxically dilation
of distal coronary vasculature with passive collapse of an
arterial segment can reduce regional coronary blood flow
(42,45). Nifedipine and other coronary vasodilators (46)
have been shown to decrease distal coronary artery pressure
(47). Thus, vasodilators, including the calcium channel
blocking drugs, may cause a "coronary steal" or an in-
appropriate distribution of blood flow to normal regions at
the expense of flow to ischemic zones (48-50) . The regional
decrease in coronary blood flow during cold pressor testing
in patients with significant left anterior coronary artery dis-
ease, while not constituting a true coronary steal, suggests
that combined beta-adrenergic and calcium channel block-
ade may cause an inhomogeneous distribution of coronary
blood flow to some potentially ischemic zones. Regional
coronary constriction after combined beta-adrenergic and
calcium channel blocking therapy may also result from ni-
fedipine-induced dilation of a proximal normal arterial seg-
ment or passive collapse of a distal vessel with a simulta-
neous further reduction of coronary blood flow due to the
metabolic or betaj-adrenergic blocking effects of propran-
olol (51,52). In addition, in the conscious dog, Vatner et
al. (30) observed that the nifedipine-induced changes in
coronary blood flow and resistance were significantly smaller
after beta-adrenergic blockade with propranolol. The atten-
uation of coronary vasodilatory responses suggests that there
may be some opposing interaction with combined drug
therapy .
Regional decreases in myocardial oxygen consumption
would be associated with appropriate decreases in regional
coronary blood flow. Intracoronary nifedipine has been shown
to depress regional left ventricular function more in ischemic
than in nonischemic myocardial zones (53). Although myo-
cardial contractility (as measured by dP/dt) was determined
after combined drug therapy, our study design did not in-
clude the evaluation of regional myocardial function and its
relation to coronary vasomotor tone.
Previous studies (15 ,17,19) suggest that the autoregu-
latory reserve is reduced or exhausted in patients with severe
coronary artery disease during cold pressor testing as per-
formed in this study. Nifedipine may reduce blood flow to
myocardium supplied by stenotic coronary arteries in re-
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gions with reduced autoregulatory capacity (27,46,54). Thus,
the extent of coronary artery disease and degree of regional
autoregulatory capacity might partly explain the different
regional cold pressor test responses observed in patients with
and without left anterior descending coronary artery stenosis.
Limitations. Certain limitations of this study should be
mentioned. Despite the inherent limitations, cold pressor
testing has a relatively consistent effect on coronary vaso-
motor responses in patients with severe coronary artery dis-
ease. Unfortunately, cold pressor testing responses in pa-
tients with less severe degrees of coronary artery disease,
and in some patients with normal coronary arteries, are
highly variable (25,26,55). The reasons for the variable
resistance responses we observed are unclear. Indeed, de-
spite similar responses of total coronary sinus resistance,
the regional resistance responses between groups with in-
significant left anterior descending coronary artery disease
(groups A1 and B1) were different. The discrepancy in
responses between groups A1 and B1 may be due to several
factors. Although both groups had minimal left anterior
descending coronary artery disease, group Al had signifi-
cantly more disease involving the circumflex and right coro-
nary arteries as well as more left ventricular wall motion
abnormalities. Regional differences in autoregulatory ca-
pacity may limit vasodilation during cold pressor testing in
myocardial zones supplied by diseased circumflex and right
coronary arteries without impairing autoregulation of the
minimally diseased left anterior descending coronary artery.
In group B1, autoregulatory vasodilation during cold pressor
testing in myocardial zones supplied by normal circumflex
and right coronary arteries may increase flow more in in-
ferior than anterior regions explaining, in part, increased
great vein resistance with no significant change in coronary
sinus (11 ± 29%, P == NS) or great cardiac vein flow
(9 ± 13%, P == NS). In addition, patients in group B1
appeared to be atypical responders to cold pressor testing.
Four of six patients in group B1 had an atypical chest pain
syndrome with normal coronary arteries, which has been
associated with abnormal coronary vasodilatory reserve and
vasoconstrictor responses to cold pressor testing (55).
Previously reported cold pressor testing responses before
and after propranolol (15) differed somewhat from the re-
sponses in this study. We believe this discrepancy may be
due to differences in the extent of atherosclerotic coronary
disease and coronary reserve in patients in groups A2 and
B2. The initial cold pressor testing responses for these two
groups together demonstrate a statistically significant in-
crease in coronary artery resistance. However, when these
patient groups are analyzed separately, the cold pressor test-
ing responses did not achieve statistical significance for
either subgroup. We can speculate that the inclusion of
patients with less than triple vessel coronary artery disease
(seven patients with 50% circumflex coronary artery disease
and five patients with insignificant right coronary artery
disease) in groups A2 and B2 accounts for the lack of a
statistically significant cold pressor testing response.
Serial coronary blood flow measurements during cold
pressor testing have been performed in similar studies (15,56),
with reproducible results varying by less than 15%. In this
study, as in other studies using the thermodilution technique,
there was a wide variability in the absolute coronary sinus
flow values. Because changes in coronary flow were small,
relative and directional changes in coronary resistance were
used to indicate important coronary responses. We are re-
luctant to attribute significance to inferior regional flow re-
sponses (total coronary sinus flow minus great vein flow)
because of the variability in the total coronary sinus flow
measurements.
Serum levels a/propranolol and nifedipine and individual
patient sensitivity to the beta-adrenergic and calcium chan-
nel blocking drugs may bea significant uncontrolled variable
affecting coronary resistance responses. The onset of action
of nifedipine after sublingual administration occurs in less
than 5 minutes, and after oral administration, usually in less
than 20 minutes (57). Although serum levels of nifedipine
or propranolol were not measured, the hemodynamic and
metabolic changes observed in our patients were less prom-
inent but consistent with those observed in patients with
coronary artery disease given propranolol or nifedipine in-
dividually (32,35,51,52) and after oral or intravenous beta-
adrenergic blocking drugs combined with 10 or 20 mg of
sublingual nifedipine (11,40).
Conclusions. Combined therapy with propranolol and
nifedipine modified coronary vasomotor responses to ad-
renergic stimulation, with regional coronary vasoconstric-
tion occurring in some patients with significant left anterior
descending coronary artery stenosis. Despite efficacy of
combined drug therapy, the clinical significance of this ob-
servation is unknown and warrants further investigation.
Although a true coronary steal phenomenon during adren-
ergic stimulation after combined drug therapy was not dem-
onstrated, an inhomogeneous distribution of coronary blood
flow to potentiallyischemic zones must beconsidered. Within
our experimental design, these data suggest that the bene-
ficial effects of combined beta-adrenergic and calcium chan-
nel blockade may be due predominantly to a reduction in
myocardial oxygen demand resulting from decreased myo-
cardial contractility, diminished left ventricular wall stress
or reduced intramyocardial resistance rather than from in-
creased myocardial oxygen supply.
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